Find out more information on why we are the experts in pest control
Sanofi Pasteur, a French pharmaceutical company, is successful in coming up with an anti-dengue vaccine after 20 years of exhaustive research. Three injections with an interval of six months were administered to children with an age range of two to 14 years old. It decreased their risk of contracting dengue by 56% as reported last April. It was also concluded that the vaccine is safe, without any adverse effects. Hence, there’s no stopping Sanofi Pasteur to apply for its licensing by early 2015. To further support their licensure application, more than 20,000 volunteers are now undergoing the vaccine’s trial in Latin America.
Furthermore, Sanofi Pasteur will be able to provide a 100 million doses of the vaccine a year. As for the price, it will be identified after the discussions with the World Health Organization and the countries who are interested in availing the said vaccine. The intention is to make it readily available first to countries that need it the most. Those countries are: the Philippines, Malaysia, Indonesia, Vietnam and Thailand, which comprise 70% of dengue cases around the world.
The anti-dengue vaccine can have the following effects given the results of Sanofi Pasteur’s Phase III Clinical Trials from 2011 – 2013 in Southeast Asia:
When the vaccine gets licensed, it has the potential to:
Apart from this preventive option against dengue, Rentokil can also help you evade the devastating effects of the said disease through fogging and other expert mosquito control options.
Call your experts in pest control at (02) 333 5888 or at our toll free hotline 1800 10 EXPERTS (397 3787).
You can also email email@example.com
To avoid dengue cases, here’s a fogging activity being done by Rentokil.